Spark Therapeutics appoints Rogerio Vivaldi as its first chief commercial officer
Late-stage gene therapy company, Spark Therapeutics, has appointed Rogerio Vivaldi as its first chief commercial officer.
He is the former head of rare diseases at Genzyme, and the former chief executive of Minerva Neurosciences. Dr Vivaldi previously served as a board member for Spark since April 2014.
The appointment comes as Spark prepares to complete its Phase III trial for SPK-RPE65, to address inherited retinal dystrophies caused by mutations in the RPE65 gene. Dr Vivaldi will oversee the planned launch of SPK-RPE65, with responsibility for global commercial, patient advocacy, market access, and medical affairs operations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze